首页>
美国卫生研究院文献>The Oncologist
>Phase II Multicenter Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
【2h】
Phase II Multicenter Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
机译：多西紫杉醇联合泼尼松联合或不联合西地尼单抗治疗的初治男性转移性去势抵抗性前列腺癌男性患者第二阶段多中心随机试验。
- 摘要
- 著录项
- 相似文献
- 相关主题
摘要
Lessons Learned. class="unordered" style="list-style-type:disc" id="onco12985-list-0001">The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological rationale and supportive early‐phase clinical results, adding antiangiogenic agents to docetaxel for mCRPC is a great challenge.
机译：得到教训。 class =“ unordered” style =“ list-style-type：disc” id =“ onco12985-list-0001”> <！-list-behavior = unordered prefix-word = mark-type = disc max-label- size = 0-> 阴性结果与大型三期试验的阴性结果一致，在该试验中，多西他赛联合抗血管生成剂用于转移性去势抵抗性前列腺癌患者（ mCRPC）。 负面数据强调，尽管有合理的生物学原理和支持的早期临床结果，但在多西紫杉醇中添加抗血管生成剂治疗mCRPC仍然是一个巨大的挑战。
著录项
- 期刊名称 The Oncologist
-
作者单位
- 年(卷),期 2019(24),9
- 年度 2019
- 页码 1149–e807
- 总页数 12
- 原文格式 PDF
- 正文语种
- 中图分类 肿瘤学;
-
关键词
相似文献
- 外文文献
- 中文文献
- 专利
-
1. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer [J] . Heath Elisabeth, Heilbrun Lance, Mannuel Heather, The oncologist . 2019,第9期
机译：II期，多中心，随机试验Docetaxel加上泼尼松，男性中有或没有Cediranib，具有化疗 - 幼稚转移性阉割前列腺癌
-
2. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer [J] . Elisabeth Heath, Ulka Vaishampayan, Philip Stella, The oncologist . 2019,第9期
机译：II期，多中心，随机试验Docetaxel加上泼尼松，男性中有或没有Cediranib，具有化疗 - 幼稚转移性阉割前列腺癌
-
3. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Petrylak Daniel P., Vogelzang Nicholas J., Budnik Nikolay, The lancet oncology . 2015,第4期
机译：多西他赛和泼尼松联合来那度胺或不联合来那度胺用于未接受化疗的转移性去势抵抗性前列腺癌（MAINSAIL）患者：一项随机，双盲，安慰剂对照的3期试验
-
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014
机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
-
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020
机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
-
6. Phase III Randomized Double-Blind Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [O] . Karim Fizazi, Robert Jones, Stephane Oudard, -1
机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松
-
7. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 [O] . Fizazi, K. (Karim), Jones, R. (Robert), Oudard, S. (Stéphane), 2015
机译：III期随机，双盲，多中心试验，在多西他赛为基础的治疗期间或之后，对转移性去势抵抗性前列腺癌患者进行了奥特隆（TAK-700）联合泼尼松与安慰剂联合泼尼松的比较：ELM-PC 5
代理获取
